Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest

Simply Wall St.

Oct 28

Recursion Pharmaceuticals (RXRX) saw its stock gain momentum as investors reacted to several developments, including its Exscientia merger, progress on new oncology drugs, and updates on upcoming late...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2578667819"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578667819\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578667819?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-10-28 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578667819","market":"sg","top_or_hot":-1,"title":"Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest","media":"Simply Wall St.","content":"<div>\n<p>Recursion Pharmaceuticals (RXRX) saw its stock gain momentum as investors reacted to several developments, including its Exscientia merger, progress on new oncology drugs, and updates on upcoming late...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-exploring-valuation-as-ai-exp\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecursion Pharmaceuticals (RXRX): Exploring Valuation as AI Expansion, Key Merger, and Clinical Progress Boost Interest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-28 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-exploring-valuation-as-ai-exp><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recursion Pharmaceuticals (RXRX) saw its stock gain momentum as investors reacted to several developments, including its Exscientia merger, progress on new oncology drugs, and updates on upcoming late...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-exploring-valuation-as-ai-exp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-exploring-valuation-as-ai-exp","article_id":"2578667819","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-exploring-valuation-as-ai-exp","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2578667819","pubTimestamp":1761658422,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recursion Pharmaceuticals (RXRX) saw its stock gain momentum as investors reacted to several developments, including its Exscientia merger, progress on new oncology drugs, and updates on upcoming late-stage clinical trials.\nSee our latest analysis for Recursion Pharmaceuticals.\nThe latest rally in Recursion Pharmaceuticals’ share price comes on the back of optimism surrounding its AI-driven drug discovery platform, major partnership news, and progress toward late-stage clinical milestones...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4588":"碎股","BK4609":"英伟达持仓股","BK4528":"SaaS概念","RXRX":"Recursion Pharmaceuticals, Inc.","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4097":"系统软件","AI":"C3.ai, Inc.","BK4023":"应用软件","BK4611":"AI医疗","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4139":"生物科技","PRGS":"Progress Software Corporation","BK4543":"AI","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念"},"translate_title":"Recursion Pharmaceuticals(RXRX)：随着人工智能扩张、关键合并和临床进展激发兴趣，探索估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"RXRX":1.5,"AI":0.7},"content_text":"Recursion Pharmaceuticals (RXRX) saw its stock gain momentum as investors reacted to several developments, including its Exscientia merger, progress on new oncology drugs, and updates on upcoming late-stage clinical trials. See our latest analysis for Recursion Pharmaceuticals. The latest rally in Recursion Pharmaceuticals’ share price comes on the back of optimism surrounding its AI-driven drug discovery platform, major partnership news, and progress toward late-stage clinical milestones. After a bumpy first half of the year, momentum has clearly shifted, with a 33% 1-month share price return helping to offset earlier declines. While total shareholder return for the past year remains negative, recent investor enthusiasm and strong news flow suggest that sentiment is warming up as the company enters a pivotal phase. Curious about other innovative healthcare names catching attention? Explore new opportunities with the See the full list for free. With the stock rallying and upcoming data on the horizon, the real question for investors is whether Recursion Pharmaceuticals is trading below its true worth, or if the recent excitement means any future upside is already included in the current price. AdvertisementMost Popular Narrative: 2.6% Undervalued Recursion Pharmaceuticals’ current share price of $6.30 sits just below the widely watched narrative fair value estimate of $6.47. The modest gap is fueling debate over what’s driving the latest analyst consensus. With that backdrop, the next quote lays out one of the most important factors behind this valuation.  Rapid integration and iterative improvement of the Recursion OS 2.0 platform, incorporating advanced AI and ML tools (such as Boltz-2 and causal AI for clinical trial design), are expected to drive faster, more cost-effective drug discovery and development, improving R&D efficiency and supporting long-term margin expansion.  Read the complete narrative. What’s the secret behind this fair value? There is a dramatic expected leap in growth that is anything but ordinary for drug developers. Want to see which aggressive future assumptions propel this number? Click to uncover the optimism and the underlying numbers that inform this narrative’s bold target. Result: Fair Value of $6.47 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent reliance on pharma partners or setbacks in clinical trials could quickly undermine Recursion’s positive outlook and challenge its prospects for long-term growth. Find out about the key risks to this Recursion Pharmaceuticals narrative. Another View: Price Ratio Tells a Different Story Looking beyond fair value narratives, market pricing tells its own tale. Recursion’s price-to-sales ratio is 42.6x, significantly higher than both its US biotech peers at 11.3x and its closest sector rivals at 15.8x. Even the modelled fair ratio is dramatically lower, which may point to considerable valuation risk if the market sentiment shifts. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:RXRX PS Ratio as at Oct 2025 Build Your Own Recursion Pharmaceuticals Narrative Prefer to approach the numbers from your own angle, or put together a different story? Dive into the data and shape your personal view in just a few minutes with Do it your way A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. Looking for More Smart Investing Ideas? Don’t wait for the next headline to move the markets. Get ahead by targeting stocks with strong fundamentals, future themes, and untapped value using powerful filters.  Target reliable passive income. Review these 19 dividend stocks with yields > 3% that consistently deliver attractive yields above 3% to help grow your portfolio’s earnings. Ride the future of automation and data. Act early with these 27 AI penny stocks that are revolutionizing industries by harnessing advanced machine learning and artificial intelligence. Unearth serious bargains. Zero in on these 870 undervalued stocks based on cash flows that may be trading below their true worth according to cash flow analysis, giving you an edge over the crowd.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}